Prostate-specific antigen and radiation therapy for clinically localized prostate cancer
- 15 May 1995
- journal article
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 32 (2), 293-306
- https://doi.org/10.1016/0360-3016(95)00077-c
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- The prognostic importance of gleason grade in prostatic adenocarcinoma: A long-term follow-up study of 648 patients treated with radiation therapyInternational Journal of Radiation Oncology*Biology*Physics, 1995
- Relationship of tumor DNA-ploidy toserum prostate-specific antigen doubling time after radiotherapy for prostate cancerUrology, 1994
- Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: Prognostic implicationsInternational Journal of Radiation Oncology*Biology*Physics, 1994
- Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostateUrology, 1993
- Observations on the doubling time of prostate cancer.The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volumeCancer, 1993
- Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapyInternational Journal of Radiation Oncology*Biology*Physics, 1992
- The effect of overall treatment time on the outcome of definitive radiotherapy for localized prostate carcinoma: The radiation therapy oncology group 75-06 and 77-06 experienceInternational Journal of Radiation Oncology*Biology*Physics, 1991
- Pelvic lymphadenectomy for staging clinically localized prostate cancer Indications, Complications, and Results in 217 CasesUrology, 1990
- The Incidence of Monotone Likelihood in the Cox ModelTechnometrics, 1981
- Estimation of confidence limits for the cumulative probability of survival in life table analysisJournal of Chronic Diseases, 1978